AVERAGE ANALYSTS PRICE TARGET $38
AVERAGE ANALYSTS RECOMMENDATION overweight
P/E RATIO 19
SHORT INTEREST
COMPANY PROFILE
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
SOURCE SEEKING ALPHA
Results from a Phase 3 clinical trial, IMvigor130, evaluating Roche's (OTCQX:RHHBY) Tecentriq (atezolizumab) plus platinum-based chemo in treatment-naive patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) showed a treatment benefit compared to chemo alone.
Specifically, patients receiving Tecentriq + chemo experienced a statistically significant reduction in the risk of cancer progression or death compared to patients receiving only chemo.
Overall survival also appeared to favor the Tecentriq group but the data are not yet mature.
No new safety signals were observed.
There are four ongoing late-studies assessing Tecentriq alone or in combination with other medicines in early and advanced bladder cancer.
The FDA granted accelerated approval to use Tecentriq as initial treatment in patients with advanced bladder cancer in April 2017. Full approval will be contingent on the successful outcomes of the late-stage studies.
AVERAGE ANALYSTS RECOMMENDATION overweight
P/E RATIO 19
SHORT INTEREST
COMPANY PROFILE
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience. The Diagnostic segment refers to diagnosis of diseases through an in vitro diagnostics process. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.
SOURCE SEEKING ALPHA
Results from a Phase 3 clinical trial, IMvigor130, evaluating Roche's (OTCQX:RHHBY) Tecentriq (atezolizumab) plus platinum-based chemo in treatment-naive patients with locally advanced or metastatic urothelial carcinoma (bladder cancer) showed a treatment benefit compared to chemo alone.
Specifically, patients receiving Tecentriq + chemo experienced a statistically significant reduction in the risk of cancer progression or death compared to patients receiving only chemo.
Overall survival also appeared to favor the Tecentriq group but the data are not yet mature.
No new safety signals were observed.
There are four ongoing late-studies assessing Tecentriq alone or in combination with other medicines in early and advanced bladder cancer.
The FDA granted accelerated approval to use Tecentriq as initial treatment in patients with advanced bladder cancer in April 2017. Full approval will be contingent on the successful outcomes of the late-stage studies.